-
公开(公告)号：US11993596B2
公开(公告)日：2024-05-28
申请号：US17259089
申请日：2019-07-12
发明人： Yunfu Luo , Jianfeng Pan , Guoli Zhang , Sheng Su , Yong Wang , Shuhui Chen
IPC分类号： C07D471/04 , A61P11/00 , C07D487/04 , C07D498/04
CPC分类号： C07D471/04 , A61P11/00 , C07D487/04 , C07D498/04
摘要： Provided is a fused tri-cyclic compound as PDE3/PDE4 dual inhibitor, and a use thereof in the preparation of drugs for PDE3/PDE4 associated diseases, particularly in medicinal functions such as chronic obstructive pulmonary disease (COPD). Provided are specifically a compound of formula (I) and a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240139208A1
公开(公告)日：2024-05-02
申请号：US18547410
申请日：2022-03-03
发明人： Fan FENG , Ding YU , Xungiang WANG , Xiquan ZHANG , Yanfeng BAI , Chaoqiang YANG , Yuying ZHANG
IPC分类号： A61K31/565 , A61K31/506 , A61P35/00
CPC分类号： A61K31/565 , A61K31/506 , A61P35/00
摘要： The present disclosure relates to a combined pharmaceutical composition containing a CDK4/6 inhibitor and a use thereof, and specifically relates to a combined pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and fulvestrant. The present disclosure further relates to a use of the combined pharmaceutical composition in treating breast cancer. The combined pharmaceutical composition of the present disclosure produces better therapeutic effects in reducing tumor growth or even eliminating tumors.
-
公开(公告)号：US11891398B2
公开(公告)日：2024-02-06
申请号：US17058308
申请日：2019-05-24
发明人： Haiying He , Jianhua Xia , Zhen Gong , Jian Li , Shuhui Chen
IPC分类号： C07D487/04 , A61P31/20
CPC分类号： C07D487/04 , A61P31/20
摘要： The present application relates to a 2,3-dihydro-1H-pyrrolizine-7-formamide derivative as a nucleoprotein inhibitor and a use in preparation of a drug for treating HBV related diseases. The present application specifically relates to a compound represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.
-
公开(公告)号：US20240002394A1
公开(公告)日：2024-01-04
申请号：US18037523
申请日：2021-11-24
发明人： Yinsheng ZHANG , Yong GAO , Yuan YIN , Wei SHI , Damin ZHAO , Gaoyuan ZHU , Xiaojin WANG , Yanpeng JI
IPC分类号： C07D495/04 , A61P35/00
CPC分类号： C07D495/04 , C07B2200/05 , A61P35/00
摘要： The present disclosure provides a deuterium-modified thienopyridone compound, a preparation method therefor, a pharmaceutical composition thereof, and a medical use thereof. The deuterium-modified thienopyridone compound is shown in formula I, and has been shown to inhibit HPK1 kinase activity, being capable of achieving an anti-tumour effect.
-
公开(公告)号：US20230405141A1
公开(公告)日：2023-12-21
申请号：US18040498
申请日：2021-08-13
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , NANJING SHUNXIN PHARMACEUTICALS CO., LTD. OF CHIATAI TIANQING PHARMACEUTICAL GROUP
发明人： Xiquan ZHANG , Tianxi CHEN , Weiwei FENG , Bing ZHANG , Xiaoqi TANG , Tongjie XU , Xiaojin WANG , Huace SHENG , Zhengping ZHANG , Hua WANG , Yong GAO
CPC分类号： A61K47/6855 , A61K47/545 , A61P35/00 , A61K47/6803 , A61K47/65
摘要： Provided is an antibody drug conjugate, specifically comprising a therapeutic antibody moiety, an intermediate linker moiety and a cytotoxic drug moiety which are linked. The therapeutic antibody moiety is an antibody against an HER2 target. The cytotoxic drug moiety is a camptothecin topoisomerase I inhibitor. The cytotoxic drug moiety or the linker-cytotoxic drug moiety is modified by means of deuterium substitution. The antibody drug conjugate can be used for the prevention or treatment of cancers.
-
公开(公告)号：US20230357242A1
公开(公告)日：2023-11-09
申请号：US18246251
申请日：2021-09-30
发明人： Yinsheng ZHANG , Yong GAO , Wei SHI , Damin ZHAO , Yuan YIN
IPC分类号： C07D471/04 , C07D519/00
CPC分类号： C07D471/04 , C07D519/00
摘要： Provided is a compound as an Akt kinase inhibitor. The present invention specifically relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating Akt kinase-related diseases.
-
公开(公告)号：US20230285554A1
公开(公告)日：2023-09-14
申请号：US18019612
申请日：2021-08-13
IPC分类号： A61K39/395 , A61K31/4709 , A61P35/00
CPC分类号： A61K39/3955 , A61K31/4709 , A61P35/00
摘要： The present application relates to the field of biomedicine, and relates to a combined medication for treating soft tissue sarcoma. The combined medication comprises an anti-PD-L1 antibody and anlotinib or a pharmaceutically acceptable salt thereof. In addition, further provided is a pharmaceutical composition comprising the anti-PD-L1 antibody and anlotinib or the pharmaceutically acceptable salt thereof, or the use of the pharmaceutical composition in preparation of a medication for treating soft tissue sarcoma.
-
公开(公告)号：US20230279138A1
公开(公告)日：2023-09-07
申请号：US18007012
申请日：2021-07-26
发明人： YOUWEI ZHU , Yingchun LI , Yanju CHENG
CPC分类号： C07K16/2887 , C07K16/2809 , A61K47/12 , A61K47/22 , A61K9/19 , A61K2039/505
摘要： The present invention provides a novel bispecific anti-CD3/CD20 polypeptide complex formulation containing a first antigen-binding portion and a second antigen-binding portion. Specifically, the formulation comprises a liquid formulation and a lyophilized formulation.
-
公开(公告)号：US20230174528A1
公开(公告)日：2023-06-08
申请号：US17922223
申请日：2021-04-29
发明人： Weiwei FENG , Yanlong LIU , Huihui ZHANG , Fei LIU , Bin WANG , Yiyan YAO , Zhilin CHEN , Jinlei ZHU , Chenghui LU
IPC分类号： C07D471/04 , A61P35/02
CPC分类号： C07D471/04 , A61P35/02 , C07B2200/13
摘要： A crystal of a trifluoromethyl/chloro disubstituted sulfonamide selective BCL-2 inhibitor, specifically related to a crystal of a compound of formula I, a preparation method therefor, and use thereof in preventing and treating diseases related to anti-apoptotic protein BCL-2, such as cancers.
-
公开(公告)号：US20230123104A1
公开(公告)日：2023-04-20
申请号：US17909708
申请日：2021-03-05
发明人： Maoyi LEI , Yu XU , Yunfu LUO , Zhenliang SHAN
IPC分类号： C07D498/04 , A61P35/00
摘要： Disclosed are a crystal of a tricyclic compound acting on CRBN protein and a preparation method therefor, specifically relating to a crystal of a compound of formula (I) and a preparation method therefor. An application of the crystal in the preparation of drugs for treating CRBN protein-related diseases is further comprised.
-
-
-
-
-
-
-
-
-
搜索结果
192 条记录 (耗时 0.064 秒)
